The US Food and Drug Administration has recently approved a number of new direct-acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug-drug interactions. These interactions must be considered both when starting and stopping any medication, including over-the-counter medications and herbal supplements. These drug-drug interactions can increase the risk of toxicity or decrease the likelihood of treatment response. Knowledge of these interactions is paramount in optimizing the success of antiviral therapy. Conclusion: In this review we summarize the available data regarding drug-drug interactions for direct-acting antiviral agents, the interactions being the most clinically relevant that are currently known; this review is intended to serve as a clinician's guide to understanding and managing these complex interactions. (HEPATOLOGY 2016;63:634-643) D irect acting antiviral agents (DAAs) have transformed the management of hepatitis C viral (HCV) infection. Virological cure rates of >90% are routinely achievable across HCV genotypes and irrespective of the presence of cirrhosis and prior non-DAA treatment history. Although highly effective and well tolerated, DAAs present unique and important potential for drug-drug interactions that must be considered before, during, and after initiation of DAAbased therapy. This review summarizes the available data regarding the most clinically relevant drug-drug interactions for DAAs with the goal of optimizing pharmacotherapeutic outcomes.

Results of this survey indicate that there is a large amount of variation in the components of PGY1 pharmacy residency programs among UHC academic medical centers. The majority of respondents reported no change in the number of residency positions offered within the past two years, but they reported an increase in the number of applications from 2009 to 2010.